Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Nabs $74M in Private Stock Placement; Cash to Flesh Out Drug Pipeline

NEW YORK, Feb. 28 (GenomeWeb News) - Perlegen Sciences has closed $74 million in a private placement of its Series D Preferred Stock with new and existing investors, the company said today.


The company will use the equity financing "to continue in-licensing and developing a ... pipeline of late-stage drugs, exploiting Perlegen's ability to target the right drugs to the right patients," Robert Middlebrook, chief corporate development officer of Perlegen, said in a statement.


CSK Venture Capital led the financing, followed by new investors Brookside Capital, an affiliate of Bain Capital; Mizuho Securities; Glynn Capital Management; CapeSecurities; and "several other" USand European institutional investors.


Previous investors also participating in the financing included Affymetrix, Alex Zaffaroni, Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, and CMEA Ventures.